Table 1.
Hepatocellular carcinoma rate of specific mutation combinations and odds ratio in comparison with basal core promoter double mutation only
| Specific mutation combinations | HCC1 rate | OR | 95%CI | P-value |
| in combination with BCP2 double mutations | ||||
| Wild-type | 3.4% (1/29) | 0.23 | 0.0048-2.0622 | 0.2391 |
| BCP double mutations only [(A1762T + G1764A)]3 | 13.6% (6/44) | 13 | ||
| Dominant quadruple mutations | ||||
| (G1613A + C1653T) | 46.2% (6/13) | 5.4286 | 5.4286-1.3530 | 0.0200 |
| (C1653T + T1753V) | 40.0% (2/5) | 4.2222 | 4.2222-0.5797 | 0.1821 |
| (C1653T + G1896A) | 27.3% (6/20) | 2.7143 | 2.7143-0.7495 | 0.1680 |
| (T1753V + G1896A) | 66.7% (14/21) | 12.6667 | 12.6667-3.6262 | 0.0000 |
| (A1846T + G1896A) | 46.2% (6/13) | 5.4286 | 5.4286-1.3530 | 0.0200 |
| Dominant combinations in sextuplet mutations: | ||||
| (G1613A + C1653T + A1846T + G1896A) | 71.4% (5/7) | 14.5142 | 1.8869-185.1359 | 0.0033 |
| (G1613A + C1653T + A1846T + G1899A) | 83.3% (5/6) | 28.2555 | 2.5885-1517.9673 | 0.0012 |
| Dominant combinations in septuplet mutations: | ||||
| (G1613A + C1653T + T1753V + A1846T + G1896A) | 100% (6/6) | Infinity | 5.4236-infinity | 0.0001 |
| (G1613A + C1653T + A1846T + G1896A + G1899A) | 85.7% (6/7) | 39.3553 | 4.0487-2018.0433 | 0.0001 |
1
Hepatocellular carcinoma;
2
Basal core promoter;
3
Reference of odds ratio analyses; P-value was calculated by Fisher’s exact test for count data. BCP: Basal core promoter; HCC: Hepatocellular carcinoma.